{"gene":"TCF7L2","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":2002,"finding":"The β-catenin/TCF-4 complex controls proliferation versus differentiation in intestinal epithelial cells by directly repressing p21(CIP1/WAF1) transcription through c-MYC; disruption of β-catenin/TCF-4 activity decreases c-MYC expression, releases p21(CIP1/WAF1) transcription, and induces G1 arrest and differentiation.","method":"Dominant-negative TCF-4 expression in CRC cell lines, reporter assays, gene expression analysis, loss-of-function experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean loss-of-function with defined mechanistic pathway (TCF-4→c-MYC→p21→G1 arrest), replicated across multiple CRC cell lines with multiple orthogonal readouts","pmids":["12408868"],"is_preprint":false},{"year":2001,"finding":"TCF-4 contains distinct binding sites for β-catenin (N-terminal first 50 amino acids) and plakoglobin (residues 51–80); CK2 phosphorylates Tcf-4 at Ser-58/59/60, reducing plakoglobin binding without affecting β-catenin binding; plakoglobin binding to TCF-4 negatively affects TCF-4 transcriptional activity.","method":"In vitro kinase assay with CK2, deletion mapping/pulldown, co-immunoprecipitation, ternary complex reconstitution, TCF-4 mutant transcriptional activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution, mutagenesis, and binding domain mapping in a single rigorous study with multiple orthogonal methods","pmids":["11711551"],"is_preprint":false},{"year":2006,"finding":"HIC1 antagonizes TCF/β-catenin-mediated transcription by physically associating with TCF-4 and recruiting TCF-4 and β-catenin to HIC1 nuclear bodies, preventing their association with TCF-binding elements of Wnt-responsive genes.","method":"Co-immunoprecipitation, nuclear body co-localization imaging, reporter assays (TOPflash), loss-of-function in Wnt-stimulated cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, live imaging of nuclear bodies, and functional reporter assay in one study with multiple orthogonal methods","pmids":["16724116"],"is_preprint":false},{"year":1999,"finding":"TCF-4 protein is highly and restrictedly expressed in intestinal crypt epithelium and mammary gland epithelium, with a temporal expression gradient along the crypt-villus axis (high in crypts, low on villi in early fetal intestine), consistent with its role in proliferative compartment maintenance.","method":"Immunohistochemistry with TCF-4-specific monoclonal antibodies on mouse and human tissues","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by IHC with tissue-specific antibodies, replicated in multiple tissue types and developmental stages; no direct functional consequence tested in this paper","pmids":["9916915"],"is_preprint":false},{"year":1998,"finding":"TCF-4 binds β-catenin and induces nuclear localization of β-catenin in expressing cells; two isoforms of mouse Tcf-4 are expressed in distinct regions of the embryonic CNS (hindbrain, diencephalon) and limb bud mesenchyme; Tcf-4 expression in the forebrain requires Pax-6.","method":"Co-immunoprecipitation of TCF-4 with β-catenin, in situ hybridization, Small eye mutant analysis (epistasis)","journal":"Mechanisms of development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP binding demonstrated, genetic epistasis (Pax6 required for Tcf-4 forebrain expression), and spatial expression in defined developmental contexts","pmids":["9784592"],"is_preprint":false},{"year":2001,"finding":"TCF-4 acts as a transcriptional repressor of the osteopontin (OPN) promoter; metastasis-inducing DNA containing CAAAG Tcf recognition sequences sequesters endogenous inhibitory TCF-4, thereby de-repressing OPN transcription and promoting metastasis.","method":"EMSA with cell extracts, Western blot identification of TCF-4/β-catenin/E-cadherin in DNA complexes, cotransfection of TCF-4 expression vector with OPN promoter-reporter construct, stable transfection, in vivo metastasis assay in syngeneic rats","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — EMSA, reporter assay, expression vector rescue, and in vivo functional validation in one study with multiple orthogonal methods","pmids":["11454716"],"is_preprint":false},{"year":2007,"finding":"Reduced TCF7L2 (Tcf-4) expression in ileal Crohn's disease correlates with decreased α-defensin expression; quantitative binding analysis shows reduced TCF7L2 binding activity at HD-5 and HD-6 promoters in ileal CD biopsies; heterozygous Tcf-4 (+/-) mice show significantly decreased Paneth cell α-defensin levels and bacterial killing activity, establishing Tcf-4 as a causal regulator of Paneth cell α-defensin expression.","method":"Quantitative nuclear extract binding assay, murine Tcf-4 heterozygous knockout model, bacterial killing assay, quantitative RT-PCR","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct promoter binding assay, heterozygous KO mouse model with specific antimicrobial phenotype, multiple orthogonal methods in one study","pmids":["17709525"],"is_preprint":false},{"year":2011,"finding":"TCF7l2 protein is expressed specifically during active remyelination (not developmental myelination) in non-dividing oligodendrocyte precursors; TCF7l2 forms a protein complex with Olig2 but not Olig1 in the context of myelin formation.","method":"Co-immunoprecipitation (TCF7l2-Olig2 complex), demyelination/remyelination mouse model (dietary cuprizone), immunofluorescence, Western blot","journal":"Cellular and molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP demonstrating specific Olig2 (not Olig1) interaction, in vivo remyelination model with temporal protein expression analysis","pmids":["22160878"],"is_preprint":false},{"year":2012,"finding":"Pancreas-specific deletion of Tcf7l2 impairs glucose-stimulated insulin secretion and GLP-1 response in isolated islets, reduces Glp1r and Ins2 expression, and impairs beta cell mass expansion on high-fat diet, demonstrating a direct role for TCF7L2 in beta cell function.","method":"Conditional knockout (Pdx1-Cre × Tcf7l2-flox), glucose tolerance tests, isolated islet insulin secretion assays, optical projection tomography for beta cell mass, quantitative PCR","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific cellular phenotype, multiple orthogonal readouts (GSIS, GLP-1 response, mass, gene expression) in one study","pmids":["22717537"],"is_preprint":false},{"year":2012,"finding":"TCF7L2 binds to promoters of gluconeogenic genes (including PEPCK pathway) and inhibits adjacent promoter occupancy by CREB, CRTC2, and FoxO1; hepatic TCF7L2 knockdown increases gluconeogenic gene expression and blood glucose, while overexpression of a nuclear TCF7L2 isoform ameliorates hyperglycemia in high-fat diet mice.","method":"ChIP (TCF7L2 binding to gluconeogenic promoters), siRNA knockdown, adenoviral overexpression, CREB/FoxO1 promoter occupancy assay, in vivo glucose tolerance tests","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP demonstrating direct promoter binding, epistatic analysis with CREB/FoxO1, in vivo rescue experiments with multiple orthogonal methods","pmids":["23028378"],"is_preprint":false},{"year":2012,"finding":"Insulin upregulates hepatic TCF7L2 expression and stimulates β-catenin Ser675 phosphorylation; TCF7L2 knockdown by siRNA increases hepatic glucose production and gluconeogenic gene expression, identifying TCF7L2 as a downstream effector of insulin signaling that represses hepatic gluconeogenesis.","method":"siRNA knockdown in hepatocytes, in vivo lithium injection (Wnt activation), TOPGAL transgenic mouse hepatic Wnt activity assay, Western blot for β-catenin Ser675 phosphorylation, glucose production assay","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with specific functional readout, in vivo Wnt activation, phosphorylation assay; single lab","pmids":["22967502"],"is_preprint":false},{"year":2014,"finding":"TCF7L2 regulates a transcriptional network in pancreatic islets in which ISL1 is a primary direct target; ISL1 in turn regulates proinsulin production and processing via MAFA, PDX1, NKX6.1, PCSK1, PCSK2, and SLC30A8; the T2D risk allele of rs7903146 is associated with increased TCF7L2 expression and decreased insulin content and secretion.","method":"RNA-sequencing of rodent and human islets with TCF7L2 manipulation, human islet gene expression profiles from 66 donors genotyped for rs7903146","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq with genotype-stratified analysis in human islets; pathway assignment supported by multiple targets; single lab","pmids":["25015099"],"is_preprint":false},{"year":2014,"finding":"In hepatoma cells, TCF7L2 directly regulates 149 target genes (by ChIP-seq proximal binding) including key regulators of glucose, lipid, and amino acid metabolism; TCF7L2 silencing enhances HNF4α expression and chromatin occupancy, and HNF4α is required for TCF7L2-mediated regulation of a subset of metabolic genes.","method":"ChIP-seq (TCF7L2 binding genome-wide), RNA-seq (time-course after Tcf7l2 silencing), co-siRNA epistasis experiments for HNF4α","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP-seq + RNA-seq + epistasis (co-siRNA) in one study with multiple orthogonal methods establishing genome-wide direct regulatory targets and mechanistic interplay with HNF4α","pmids":["25414334"],"is_preprint":false},{"year":2015,"finding":"Impaired LRP6 activity in LRP6(R611C) mice leads to diminished TCF7L2 activity and increased Sp1-dependent PDGF signaling, promoting loss of VSMC differentiation; Wnt3a administration restores TCF7L2-dependent VSMC differentiation and rescues post-carotid-injury neointima formation.","method":"LRP6(R611C) knock-in mouse model, carotid injury model, Wnt3a administration rescue, molecular analysis of PDGF/TCF7L2/Sp1 pathway","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic model with rescue experiment, pathway mechanistic dissection; single lab","pmids":["26489464"],"is_preprint":false},{"year":2017,"finding":"Tcf7l2 activity in pancreatic pericytes is required for β-cell function; pericyte-specific Tcf7l2 inactivation impairs glucose tolerance and glucose-stimulated insulin secretion; Tcf7l2-dependent pericytic expression of secreted factors including BMP4 supports β-cell function, and exogenous BMP4 rescues impaired insulin secretion.","method":"Pericyte-specific Tcf7l2 conditional knockout mice, glucose tolerance tests, isolated islet GSIS, BMP4 rescue experiment, gene expression analysis","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined functional rescue (BMP4), multiple phenotypic readouts, identifies a paracrine mechanism","pmids":["29246974"],"is_preprint":false},{"year":2017,"finding":"Alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion at low glucose, reduces alpha cell mass, and increases glucose infusion rates during hypoglycaemic clamp, demonstrating a cell-autonomous role for TCF7L2 in pancreatic alpha cell function and counter-regulatory responses.","method":"Alpha cell-selective Tcf7l2 KO (PPGCre × Tcf7l2-flox), hyperinsulinaemic-hypoglycaemic clamp, isolated islet glucagon secretion assay","journal":"Diabetologia","confidence":"High","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with specific physiological phenotype, clamp assay and ex vivo islet studies, multiple orthogonal readouts","pmids":["28343277"],"is_preprint":false},{"year":2018,"finding":"TCF7L2 protein is required for regulation of Wnt signaling during adipogenesis; TCF7L2 expression increases during adipogenesis in 3T3-L1 cells; inactivation of TCF7L2's HMG-box DNA-binding domain in mature adipocytes in vivo leads to whole-body glucose intolerance, hepatic insulin resistance, subcutaneous adipose hypertrophy, and inflammation.","method":"In vitro adipogenesis assays (3T3-L1 and primary adipocyte stem cells), adipocyte-specific TCF7L2 HMG-box deletion mouse model, glucose tolerance tests, ChIP-seq and RNA-seq in adipocytes","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — HMG-box domain deletion (functional mutagenesis), in vivo adipocyte-specific KO, ChIP-seq genome-wide binding, multiple orthogonal methods","pmids":["29317436"],"is_preprint":false},{"year":2019,"finding":"Adipocyte-specific deletion of Tcf7l2 leads to adipocyte hypertrophy, impaired glucose tolerance, insulin resistance, reduced triglyceride hydrolase expression, and impaired fasting-induced free fatty acid release; ChIP-seq shows TCF7L2 directly binds and regulates genes involved in lipid and glucose metabolism in adipocytes.","method":"Adipocyte-specific Tcf7l2 KO mouse (Adipoq-Cre), high-fat diet challenge, ChIP-seq, RNA-seq, lipolysis assay, glucose/insulin tolerance tests","journal":"Molecular metabolism","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — adipocyte-specific KO with ChIP-seq and RNA-seq, multiple metabolic phenotypic readouts","pmids":["30948248"],"is_preprint":false},{"year":2019,"finding":"MALAT1 enhances TCF7L2 mRNA translation via upregulation of SRSF1 and activation of the mTORC1-4EBP1 axis; MALAT1 increases TCF7L2 mRNA association with heavy polysomes likely through the TCF7L2 5′UTR; knockdown of TCF7L2 abolishes MALAT1's effects on glucose metabolism and tumorigenicity.","method":"Polysome fractionation, 5′UTR-reporter assays, pharmacological/genetic mTOR inhibition, hypophosphorylated 4EBP1 mutant expression, siRNA knockdown","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — polysome fractionation and 5′UTR reporter assays with mTOR inhibition and epistasis; single lab with multiple orthogonal methods","pmids":["30914432"],"is_preprint":false},{"year":2019,"finding":"TCF7L2 is densely expressed in the medial habenula (mHb) and regulates nicotinic acetylcholine receptor function there; inhibition of TCF7L2 signaling in the mHb increases nicotine intake; nicotine increases blood glucose via TCF7L2-dependent stimulation of the mHb; virus tracing identifies a polysynaptic mHb-to-pancreas connection; mutant Tcf7l2 rats are resistant to nicotine-induced blood glucose dysregulation.","method":"Viral TCF7L2 inhibition in the mHb, nicotine self-administration assay, anterograde/retrograde viral tracing, Tcf7l2 mutant rat model, blood glucose and glucagon/insulin measurements","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo methods (viral inhibition, mutant rat, circuit tracing), functional rescue/genetic resistance, published in high-impact journal","pmids":["31619789"],"is_preprint":false},{"year":2020,"finding":"TCF7L2 regulates postmitotic differentiation programmes in the thalamus, functioning as a thalamic terminal selector; loss of Tcf7l2 disrupts thalamo-habenular connectivity, regional transcription factor expression, cell migration/axon guidance genes, and impairs terminal electrophysiological features (firing modes) of thalamic neurons; many of these genes are direct TCF7L2 targets.","method":"Complete and conditional Tcf7l2 knockout mice, postnatal Tcf7l2 KO, electrophysiology, ChIP for direct target identification, RNA-seq","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple KO models (embryonic and postnatal conditional), electrophysiology, ChIP for direct targets, multiple orthogonal methods","pmids":["32675279"],"is_preprint":false},{"year":2021,"finding":"TCF7L2 directly represses BMP4 transcription by binding to the Bmp4 gene regulatory element in oligodendrocytes; disruption of TCF7l2 in mice causes oligodendroglial BMP4 upregulation and canonical BMP4 signaling activation; enforced TCF7l2 expression promotes oligodendrocyte differentiation by reducing autocrine BMP4 secretion; compound genetic deletion of oligodendroglial BMP4 rescues arrested OL differentiation caused by TCF7l2 disruption.","method":"Tcf7l2 conditional KO in oligodendrocytes, BMP4 conditional KO (compound genetics/epistasis), ChIP (TCF7l2 binding to Bmp4 regulatory element), in vitro OL differentiation assays","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP demonstrating direct Bmp4 binding, compound genetic rescue (epistasis), multiple in vivo and in vitro readouts, mechanistically rigorous","pmids":["33452226"],"is_preprint":false},{"year":2016,"finding":"TCF7L2 mediates thalamic-specific nuclear translocation of β-catenin in response to lithium; silencing Tcf7l2 in thalamic neurons prevents β-catenin from entering the nucleus even under lithium treatment; ectopic Tcf7l2 expression in cortical neurons shifts β-catenin to the nucleus; Tcf7l2 knockdown in zebrafish abolishes lithium's behavioral effects.","method":"Lentiviral Tcf7l2 silencing in thalamic neurons, ectopic Tcf7l2 expression in cortical neurons, nuclear fractionation, immunofluorescence, zebrafish tcf7l2 knockdown behavioral assay","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific silencing and ectopic expression with nuclear fractionation, in vivo zebrafish behavioral epistasis; single lab","pmids":["27793772"],"is_preprint":false},{"year":2023,"finding":"TCF7L2 is the dominant Wnt effector in postnatal astrocytes; conditional Tcf7l2 KO in postnatal astrocytes enlarges astrocytes, disrupts tiling and gap junction coupling, increases cortical excitatory and inhibitory synapse numbers, and increases adult social interaction, demonstrating a cell-autonomous role for TCF7L2-dependent Wnt/β-catenin signaling in astrocyte maturation and synapse number restriction.","method":"Postnatal astrocyte-specific Tcf7l2 conditional KO mice, astrocyte morphology and tiling analysis, gap junction coupling assay, synapse quantification, behavioral testing","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — astrocyte-specific KO with defined cellular (tiling, gap junctions) and circuit (synapse numbers) phenotypes plus behavioral readout, multiple orthogonal methods","pmids":["37798419"],"is_preprint":false},{"year":2005,"finding":"TIS7 downregulates β-catenin/TCF-4 transcriptional activity through interaction with histone deacetylase-containing complexes; TIS7 overexpression leads to β-catenin interaction with enzymatically active histone deacetylases; TIS7 homologous deletion in mouse embryonic fibroblasts increases TOPflash reporter activity and expression of c-Myc and OPN.","method":"TOPflash reporter assay, co-immunoprecipitation with histone deacetylases, TIS7 knockout MEFs, TIS7 overexpression, gene expression analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with enzymatically active HDAC complex, KO and OE functional data, reporter assay; single lab with multiple methods","pmids":["16204248"],"is_preprint":false},{"year":2011,"finding":"TCF7L2 splice variants have distinct effects on β-cell survival and function: clone B1 (lacking exons 13–16) induces β-cell apoptosis, impairs function, and inhibits Wnt signaling, while clones B3 and B7 (containing exon 13) improve β-cell survival and function and activate Wnt signaling; TCF7L2 depletion activates GSK3β independently of ER stress.","method":"TCF7L2 splice variant overexpression and knockdown in human isolated islets, apoptosis assays, GSIS, TOPflash/FOPflash reporter assay, GSK3β activity measurement","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific functional dissection in primary human islets with multiple orthogonal readouts; single lab","pmids":["21357677"],"is_preprint":false},{"year":2012,"finding":"TCF7L2 overexpression in isolated exocrine cells induces duct cell proliferation and islet-like cell cluster (ICC) formation in a JAK2/STAT3-dependent manner, suggesting a role for TCF7L2 in beta cell regeneration from ductal epithelium.","method":"Adenoviral TCF7L2 overexpression in isolated exocrine cells, JAK2/STAT3 pathway inhibition, quantification of ICC formation, in vivo high-fat diet and streptozotocin mouse models","journal":"Diabetologia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct overexpression with pathway inhibition (JAK2/STAT3 epistasis), in vivo corroborative models; single lab","pmids":["22945304"],"is_preprint":false},{"year":2018,"finding":"TCF7L2 binds directly to the PIK3R1 promoter at evolutionarily conserved TCF7L2-binding motifs and inhibits PIK3R1/PI3K p85 expression, thereby activating PI3K/AKT signaling and stimulating insulin secretion in pancreatic β-cells.","method":"ChIP-PCR, luciferase reporter assay, lentiviral TCF7L2 knockdown/overexpression, Western blot for PI3K p85 and p-AKT, ELISA for insulin secretion","journal":"Diabetology & metabolic syndrome","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, reporter assay, gain/loss-of-function with functional insulin secretion readout; single lab","pmids":["31312258"],"is_preprint":false},{"year":2018,"finding":"TCF7L2 and EGR1 synergistically activate LCN2 transcription by directly binding to their respective sites within the LCN2 promoter (-273/-209 for TCF7L2; -710/-616 for EGR1) via the ERK signaling pathway; recombinant LCN2 further enhances ERK activation and TCF7L2/EGR1 expression in a positive feedback loop.","method":"ChIP, luciferase reporter with deletion mapping, MEK inhibitor (U0126) epistasis, overexpression and knockdown, migration/invasion assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — ChIP demonstrating direct TCF7L2 promoter binding, deletion mapping, pathway epistasis (MEK inhibitor); single lab with multiple orthogonal methods","pmids":["30557604"],"is_preprint":false},{"year":2022,"finding":"In a Huntington's disease mouse model, TCF7L2-dependent transcription is repressed; in vivo Tcf7l2 overexpression restores myelin gene expression and remyelination in demyelinated R6/2 mice, causally linking impaired TCF7L2-dependent transcription to poor myelination in HD.","method":"RNA-sequencing of HD mouse callosal white matter and OPCs, proteomic analysis, in vivo Tcf7l2 overexpression (viral vector) in R6/2 mice, cuprizone demyelination/remyelination assay","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo gene overexpression rescue in disease model, transcriptomic and proteomic network analysis; single lab","pmids":["36044851"],"is_preprint":false},{"year":2021,"finding":"Upregulation of TCF7L2 in vascular smooth muscle cells is associated with BCL2 repression and promotes VSMC apoptosis, which is a potential driver of thoracic aortic aneurysm; the TAA genetic association at the TCF7L2 locus colocalizes with an aortic eQTL of TCF7L2.","method":"In vitro TCF7L2 upregulation experiment in VSMCs, BCL2 expression assay, eQTL colocalization analysis","journal":"American journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — in vitro overexpression with single molecular readout (BCL2); broader claim rests on eQTL colocalization; limited mechanistic depth","pmids":["34265237"],"is_preprint":false},{"year":2020,"finding":"Adipocyte-specific Tcf7l2 deletion leads to impaired glucose tolerance, increased fat mass, reduced incretin (GLP-1 and GIP) levels, and increased circulating NEFA and FABP4, with a sexually dimorphic phenotype (males only), suggesting TCF7L2 in adipocytes regulates pancreatic islet and enteroendocrine cell function via paracrine/endocrine mechanisms.","method":"Adipoq-Cre × Tcf7l2-flox conditional KO mice, normal chow and high-fat diet challenge, in vitro GSIS, incretin measurements, NEFA and FABP4 plasma assays","journal":"Diabetologia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with multiple hormonal and metabolic readouts; proposed paracrine mechanism is inferred but not directly demonstrated; single lab","pmids":["33068125"],"is_preprint":false}],"current_model":"TCF7L2 (TCF-4) is a HMG-box transcription factor that forms a bipartite complex with β-catenin to serve as the principal nuclear effector of canonical Wnt signaling; it directly binds TCF/LEF response elements to activate or repress target genes (including c-MYC, p21, OPN, BMP4, PIK3R1, gluconeogenic genes, LCN2, and Paneth cell α-defensins), interacts with co-regulators including plakoglobin (at a distinct N-terminal site phosphorylated by CK2), HIC1 (which sequesters it to nuclear bodies), Olig2, and histone deacetylase complexes; it controls intestinal crypt proliferation versus differentiation, pancreatic beta- and alpha-cell function (insulin and glucagon secretion), hepatic gluconeogenesis (by blocking CREB/FoxO1 promoter occupancy), adipocyte metabolism, oligodendrocyte differentiation (by directly repressing BMP4), thalamic neuronal terminal differentiation, astrocyte maturation and synapse number restriction, and habenular regulation of a brain-pancreas axis linking nicotine to glucose homeostasis."},"narrative":{"mechanistic_narrative":"TCF7L2 (TCF-4) is an HMG-box transcription factor that serves as the principal nuclear effector of canonical Wnt signaling, binding β-catenin through its N-terminal first 50 residues and directing transcriptional activation or repression of target genes that govern proliferation, differentiation, and metabolism [PMID:11711551, PMID:9784592]. Its co-regulatory output is tuned by competing partners: plakoglobin binds an adjacent N-terminal site (residues 51–80) and dampens activity in a manner controlled by CK2 phosphorylation at Ser-58/59/60 [PMID:11711551], HIC1 sequesters TCF-4/β-catenin into nuclear bodies away from Wnt-responsive elements [PMID:16724116], and TIS7 recruits histone deacetylase complexes to repress TCF-4 output [PMID:16204248]. In the intestine, TCF-4 maintains the proliferative crypt compartment by repressing p21(CIP1/WAF1) through c-MYC, and its disruption triggers G1 arrest and differentiation [PMID:12408868, PMID:9916915]; it also drives Paneth cell α-defensin expression, with reduced binding underlying diminished antimicrobial output in ileal Crohn's disease [PMID:17709525]. Genome-wide, TCF7L2 directly binds and regulates large programs of glucose, lipid, and amino acid metabolic genes, acting through interplay with HNF4α in liver [PMID:25414334] and across adipocytes where loss of its HMG-box DNA-binding function produces glucose intolerance, insulin resistance, and adipocyte hypertrophy [PMID:29317436, PMID:30948248]. In the pancreas it controls β-cell insulin secretion and mass via an ISL1-centered network and by repressing PIK3R1 to activate PI3K/AKT [PMID:22717537, PMID:25015099, PMID:31312258], supports α-cell glucagon secretion and counter-regulation [PMID:28343277], and acts non-cell-autonomously through pericytic BMP4 [PMID:29246974]; in liver it represses gluconeogenesis downstream of insulin by blocking CREB/CRTC2/FoxO1 promoter occupancy [PMID:23028378, PMID:22967502]. In the nervous system TCF7L2 functions as a thalamic terminal selector [PMID:32675279], drives astrocyte maturation and synapse-number restriction [PMID:37798419], promotes oligodendrocyte differentiation by directly repressing BMP4 [PMID:33452226], and in the medial habenula links nicotine to glucose homeostasis through a polysynaptic brain-pancreas circuit [PMID:31619789].","teleology":[{"year":1998,"claim":"Established that TCF-4 physically binds β-catenin and drives its nuclear localization, placing TCF-4 as a Wnt pathway transcriptional partner with spatially defined developmental expression.","evidence":"Co-IP of TCF-4 with β-catenin, in situ hybridization, and Pax-6 epistasis in mouse embryos","pmids":["9784592"],"confidence":"Medium","gaps":["Direct target genes not defined","Functional consequence of nuclear β-catenin recruitment not tested in this study"]},{"year":1999,"claim":"Localized TCF-4 protein to the proliferative crypt and mammary epithelium with a crypt-villus gradient, anchoring its inferred role in proliferative compartment maintenance.","evidence":"IHC with TCF-4-specific monoclonal antibodies on mouse and human tissue","pmids":["9916915"],"confidence":"Medium","gaps":["No functional perturbation in this study","Does not establish which target genes drive the proliferative role"]},{"year":2001,"claim":"Resolved the bipartite N-terminal architecture of TCF-4 and its phospho-regulation, showing β-catenin and plakoglobin bind distinct sites and CK2 phosphorylation selectively reduces inhibitory plakoglobin binding.","evidence":"In vitro CK2 kinase assay, deletion mapping, Co-IP, ternary complex reconstitution, and mutant transcriptional assays","pmids":["11711551"],"confidence":"High","gaps":["In vivo relevance of CK2 phosphorylation not established","Effect on specific endogenous target genes not tested"]},{"year":2001,"claim":"Demonstrated TCF-4 can act as a direct transcriptional repressor (of osteopontin) and that DNA decoy sequences titrating endogenous TCF-4 de-repress targets to promote metastasis, showing context-dependent repressive output.","evidence":"EMSA, OPN promoter-reporter cotransfection, and in vivo syngeneic rat metastasis assay","pmids":["11454716"],"confidence":"High","gaps":["Co-regulator partners mediating repression not defined here","Generalizability across promoters not addressed"]},{"year":2002,"claim":"Defined the core intestinal mechanism: β-catenin/TCF-4 maintains proliferation by repressing p21 via c-MYC, and its loss drives G1 arrest and differentiation.","evidence":"Dominant-negative TCF-4 in CRC lines with reporter and expression analyses","pmids":["12408868"],"confidence":"High","gaps":["Does not address normal homeostatic crypt dynamics in vivo","Other downstream targets contributing to differentiation not enumerated"]},{"year":2006,"claim":"Identified a negative regulatory mechanism in which HIC1 sequesters TCF-4/β-catenin into nuclear bodies, spatially uncoupling the complex from Wnt-responsive promoters.","evidence":"Reciprocal Co-IP, nuclear body co-localization imaging, and TOPflash reporter assays","pmids":["16724116"],"confidence":"High","gaps":["Stoichiometry and dynamics of sequestration unresolved","Physiological contexts where HIC1 controls TCF-4 not mapped"]},{"year":2005,"claim":"Showed TCF-4 output is repressed by TIS7-mediated recruitment of HDAC complexes, providing a chromatin-modifying brake on β-catenin/TCF-4 transcription.","evidence":"TOPflash assay, Co-IP with active HDACs, and TIS7 KO MEF gene expression analysis","pmids":["16204248"],"confidence":"Medium","gaps":["Direct vs indirect TIS7-TCF-4 contact not fully resolved","Single lab"]},{"year":2007,"claim":"Established TCF7L2 as a causal regulator of Paneth cell α-defensin expression, linking reduced TCF7L2 binding to impaired antimicrobial defense in ileal Crohn's disease.","evidence":"Quantitative promoter binding assay, Tcf-4 heterozygous KO mice, and bacterial killing assays","pmids":["17709525"],"confidence":"High","gaps":["Whether the human disease association is causal or correlative not settled","Direct defensin promoter occupancy in vivo not shown"]},{"year":2011,"claim":"Connected TCF7L2 to oligodendrocyte biology, showing remyelination-specific expression and a selective Olig2 (not Olig1) protein complex.","evidence":"Co-IP and cuprizone demyelination/remyelination mouse model with temporal expression","pmids":["22160878"],"confidence":"Medium","gaps":["Functional consequence of the Olig2 complex not tested here","Direct target genes in oligodendrocytes not identified"]},{"year":2011,"claim":"Dissected TCF7L2 splice-variant function in β-cells, showing isoform-specific opposite effects on survival, function, and Wnt activity, with depletion activating GSK3β.","evidence":"Variant overexpression/knockdown in human islets, apoptosis and GSIS assays, TOPflash, GSK3β activity","pmids":["21357677"],"confidence":"Medium","gaps":["Endogenous isoform ratios in disease not quantified","Single lab"]},{"year":2012,"claim":"Demonstrated a cell-autonomous β-cell requirement for TCF7L2 in glucose-stimulated insulin secretion, incretin response, and mass expansion.","evidence":"Pdx1-Cre conditional KO, GTT, isolated islet GSIS, and beta cell mass tomography","pmids":["22717537"],"confidence":"High","gaps":["Direct islet target genes not defined in this study","Relation to T2D risk allele not addressed here"]},{"year":2012,"claim":"Defined a hepatic anti-gluconeogenic mechanism: TCF7L2 binds gluconeogenic promoters and blocks CREB/CRTC2/FoxO1 occupancy, with knockdown raising glucose and a nuclear isoform rescuing hyperglycemia.","evidence":"ChIP, siRNA knockdown, adenoviral overexpression, and in vivo GTT","pmids":["23028378"],"confidence":"High","gaps":["Co-regulator basis of CREB/FoxO1 displacement unresolved","Isoform-specific contributions not fully separated"]},{"year":2012,"claim":"Placed hepatic TCF7L2 downstream of insulin signaling as a repressor of gluconeogenesis, with insulin inducing TCF7L2 and β-catenin Ser675 phosphorylation.","evidence":"Hepatocyte siRNA, in vivo lithium Wnt activation, TOPGAL reporter, and glucose production assays","pmids":["22967502"],"confidence":"Medium","gaps":["Direct insulin-to-TCF7L2 transcriptional link not fully mapped","Single lab"]},{"year":2012,"claim":"Linked TCF7L2 overexpression to ductal-to-islet regeneration via JAK2/STAT3, expanding its role to β-cell neogenesis.","evidence":"Adenoviral overexpression in exocrine cells with JAK2/STAT3 inhibition and in vivo HFD/STZ models","pmids":["22945304"],"confidence":"Medium","gaps":["Physiological contribution of this pathway uncertain","Single lab"]},{"year":2014,"claim":"Defined a pancreatic islet transcriptional network in which ISL1 is a primary direct TCF7L2 target controlling proinsulin production, and linked the rs7903146 risk allele to altered TCF7L2 expression and insulin content.","evidence":"RNA-seq of rodent and human islets with TCF7L2 manipulation and genotype-stratified human islet profiling","pmids":["25015099"],"confidence":"Medium","gaps":["Direction of allelic effect on TCF7L2 activity debated","Single lab"]},{"year":2014,"claim":"Mapped genome-wide direct hepatic TCF7L2 targets and revealed mutual antagonism with HNF4α in metabolic gene regulation.","evidence":"ChIP-seq, time-course RNA-seq after silencing, and co-siRNA epistasis for HNF4α","pmids":["25414334"],"confidence":"High","gaps":["Mechanism of HNF4α chromatin displacement not resolved","In vivo confirmation of the HNF4α interplay limited"]},{"year":2015,"claim":"Linked LRP6-dependent Wnt signaling to TCF7L2 activity in vascular smooth muscle, where diminished TCF7L2 promotes Sp1/PDGF-driven dedifferentiation rescuable by Wnt3a.","evidence":"LRP6(R611C) knock-in mice, carotid injury model, and Wnt3a rescue","pmids":["26489464"],"confidence":"Medium","gaps":["Direct TCF7L2 VSMC targets not defined","Single lab"]},{"year":2016,"claim":"Showed TCF7L2 is required for thalamic-specific lithium-induced nuclear translocation of β-catenin, establishing a tissue-selective gating of Wnt nuclear signaling.","evidence":"Lentiviral silencing, ectopic expression in cortical neurons, nuclear fractionation, and zebrafish behavioral knockdown","pmids":["27793772"],"confidence":"Medium","gaps":["Molecular basis of thalamic specificity unresolved","Single lab"]},{"year":2017,"claim":"Established a cell-autonomous α-cell role for TCF7L2 in glucagon secretion, α-cell mass, and counter-regulatory hypoglycemic responses.","evidence":"Alpha cell-selective KO with hyperinsulinaemic-hypoglycaemic clamp and islet glucagon assays","pmids":["28343277"],"confidence":"High","gaps":["Direct α-cell target genes not enumerated","Mechanism of low-glucose secretion control unresolved"]},{"year":2017,"claim":"Revealed a paracrine mechanism: pericytic TCF7L2 supports β-cell function via secreted factors including BMP4, with exogenous BMP4 rescuing impaired insulin secretion.","evidence":"Pericyte-specific conditional KO, GTT, islet GSIS, and BMP4 rescue","pmids":["29246974"],"confidence":"High","gaps":["Full secretome mediating the effect not defined","Direct BMP4 promoter regulation in pericytes not shown"]},{"year":2018,"claim":"Established that TCF7L2 HMG-box DNA-binding function in adipocytes regulates Wnt signaling during adipogenesis and is required for systemic glucose homeostasis.","evidence":"3T3-L1 adipogenesis assays, adipocyte-specific HMG-box deletion mice, ChIP-seq, and RNA-seq","pmids":["29317436"],"confidence":"High","gaps":["Distinction between DNA-binding-dependent and -independent functions incomplete","Specific causal adipocyte targets not pinpointed"]},{"year":2018,"claim":"Showed TCF7L2 directly represses PIK3R1 to activate PI3K/AKT and stimulate β-cell insulin secretion.","evidence":"ChIP-PCR, luciferase reporter, knockdown/overexpression, and insulin secretion ELISA","pmids":["31312258"],"confidence":"Medium","gaps":["In vivo confirmation lacking","Single lab"]},{"year":2018,"claim":"Identified TCF7L2/EGR1 synergistic activation of LCN2 via ERK signaling in a positive feedback loop, extending TCF7L2 to ERK-coupled transcription.","evidence":"ChIP, deletion-mapped reporters, MEK inhibitor epistasis, and migration/invasion assays","pmids":["30557604"],"confidence":"Medium","gaps":["Physiological relevance of the loop unestablished","Single lab"]},{"year":2019,"claim":"Defined adipocyte-autonomous TCF7L2 control of lipid and glucose metabolic genes, with deletion causing hypertrophy, insulin resistance, and impaired lipolysis.","evidence":"Adipoq-Cre KO, HFD challenge, ChIP-seq, RNA-seq, and lipolysis assays","pmids":["30948248"],"confidence":"High","gaps":["Hierarchy of direct vs secondary metabolic targets incomplete","Crosstalk with hepatic phenotype not dissected"]},{"year":2019,"claim":"Showed MALAT1 enhances TCF7L2 mRNA translation via SRSF1 and the mTORC1-4EBP1 axis, adding a post-transcriptional layer to TCF7L2 regulation relevant to glucose metabolism and tumorigenicity.","evidence":"Polysome fractionation, 5′UTR reporters, mTOR inhibition, and siRNA epistasis","pmids":["30914432"],"confidence":"Medium","gaps":["Direct MALAT1-TCF7L2 mRNA interaction not fully demonstrated","Single lab"]},{"year":2019,"claim":"Established a brain-pancreas axis in which medial habenular TCF7L2 regulates nicotinic receptor function and nicotine-induced glucose dysregulation through a polysynaptic mHb-to-pancreas circuit.","evidence":"Viral mHb inhibition, nicotine self-administration, circuit tracing, and mutant Tcf7l2 rats","pmids":["31619789"],"confidence":"High","gaps":["Transcriptional targets mediating nAChR control not defined","Molecular link from mHb signaling to islet output incomplete"]},{"year":2020,"claim":"Defined TCF7L2 as a thalamic terminal selector controlling postmitotic differentiation, connectivity, and firing properties through direct target genes.","evidence":"Embryonic and postnatal conditional KO, electrophysiology, ChIP, and RNA-seq","pmids":["32675279"],"confidence":"High","gaps":["Full direct target set incompletely catalogued","Mechanism of terminal-selector specificity unresolved"]},{"year":2020,"claim":"Showed adipocyte TCF7L2 loss produces sexually dimorphic glucose intolerance and altered incretin/NEFA profiles, implicating adipocyte-to-islet/enteroendocrine crosstalk.","evidence":"Adipoq-Cre KO with chow/HFD, GSIS, incretin and lipid measurements","pmids":["33068125"],"confidence":"Medium","gaps":["Proposed paracrine/endocrine mediators not directly demonstrated","Basis of sex dimorphism unknown"]},{"year":2021,"claim":"Defined the oligodendrocyte differentiation mechanism: TCF7L2 directly represses Bmp4, and BMP4 deletion rescues differentiation arrested by TCF7L2 loss.","evidence":"Oligodendrocyte and BMP4 conditional KOs, compound genetic epistasis, ChIP, and in vitro differentiation","pmids":["33452226"],"confidence":"High","gaps":["Co-factors at the Bmp4 element not identified","Wnt-dependence of this repression not fully resolved"]},{"year":2021,"claim":"Associated VSMC TCF7L2 upregulation with BCL2 repression and apoptosis as a candidate driver of thoracic aortic aneurysm, supported by aortic eQTL colocalization.","evidence":"In vitro VSMC overexpression with BCL2 readout and eQTL colocalization","pmids":["34265237"],"confidence":"Low","gaps":["Single in vitro molecular readout (BCL2); no in vivo causal test","Direct BCL2 promoter regulation not shown","Disease link rests on colocalization"]},{"year":2022,"claim":"Causally linked impaired TCF7L2-dependent transcription to poor myelination in Huntington's disease by restoring remyelination with Tcf7l2 overexpression.","evidence":"RNA-seq/proteomics of HD white matter and in vivo Tcf7l2 overexpression rescue in R6/2 mice","pmids":["36044851"],"confidence":"Medium","gaps":["Mechanism repressing TCF7L2 in HD unresolved","Single lab"]},{"year":2023,"claim":"Established TCF7L2 as the dominant astrocytic Wnt effector controlling astrocyte maturation, tiling, gap-junction coupling, and synapse-number restriction with behavioral consequences.","evidence":"Postnatal astrocyte-specific conditional KO with morphology, coupling, synapse, and behavioral assays","pmids":["37798419"],"confidence":"High","gaps":["Direct astrocytic target genes restricting synapse number not defined","Molecular link to behavioral phenotype incomplete"]},{"year":null,"claim":"How TCF7L2 selects activation versus repression and tissue-specific direct target sets across its many roles, and which co-regulator/isoform configurations drive each context, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Unified model linking isoform/co-regulator composition to activator vs repressor output is lacking","Tissue-specific direct target catalogs only partially defined","Mechanism of tissue-selective β-catenin gating not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,9,12,16,20,21,27,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9,12,16,21,27,28]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,4,22]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[2,22]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,13,22,26,28]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,9,12,16,20,21]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[9,12,17,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,20,21,23]}],"complexes":[],"partners":["CTNNB1","JUP","HIC1","OLIG2","HNF4A","EGR1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NQB0","full_name":"Transcription factor 7-like 2","aliases":["HMG box transcription factor 4","T-cell-specific transcription factor 4","T-cell factor 4","TCF-4","hTCF-4"],"length_aa":619,"mass_kda":67.9,"function":"Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as a repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine","subcellular_location":"Nucleus, PML body; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q9NQB0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TCF7L2","classification":"Not Classified","n_dependent_lines":94,"n_total_lines":1208,"dependency_fraction":0.07781456953642384},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TCF7L2","total_profiled":1310},"omim":[{"mim_id":"621249","title":"ARB2 COTRANSCRIPTIONAL REGULATOR A; ARB2A","url":"https://www.omim.org/entry/621249"},{"mim_id":"619403","title":"COLON CANCER-ASSOCIATED TRANSCRIPT 2, NONCODING; CCAT2","url":"https://www.omim.org/entry/619403"},{"mim_id":"616319","title":"RING FINGER PROTEIN 138; RNF138","url":"https://www.omim.org/entry/616319"},{"mim_id":"614316","title":"VESICLE TRANSPORT THROUGH INTERACTION WITH T-SNARES 1A; VTI1A","url":"https://www.omim.org/entry/614316"},{"mim_id":"613219","title":"FASTING PLASMA GLUCOSE LEVEL QUANTITATIVE TRAIT LOCUS 2; FGQTL2","url":"https://www.omim.org/entry/613219"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TCF7L2"},"hgnc":{"alias_symbol":["TCF-4"],"prev_symbol":["TCF4"]},"alphafold":{"accession":"Q9NQB0","domains":[{"cath_id":"1.10.30.10","chopping":"355-412","consensus_level":"high","plddt":93.4984,"start":355,"end":412}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NQB0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NQB0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NQB0-F1-predicted_aligned_error_v6.png","plddt_mean":53.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TCF7L2","jax_strain_url":"https://www.jax.org/strain/search?query=TCF7L2"},"sequence":{"accession":"Q9NQB0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NQB0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NQB0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NQB0"}},"corpus_meta":[{"pmid":"12408868","id":"PMC_12408868","title":"The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12408868","citation_count":1703,"is_preprint":false},{"pmid":"17476472","id":"PMC_17476472","title":"TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis.","date":"2007","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17476472","citation_count":281,"is_preprint":false},{"pmid":"17709525","id":"PMC_17709525","title":"The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17709525","citation_count":230,"is_preprint":false},{"pmid":"11313997","id":"PMC_11313997","title":"The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11313997","citation_count":174,"is_preprint":false},{"pmid":"35279145","id":"PMC_35279145","title":"Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35279145","citation_count":156,"is_preprint":false},{"pmid":"25015099","id":"PMC_25015099","title":"TCF7L2 is a master regulator of insulin production and processing.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25015099","citation_count":152,"is_preprint":false},{"pmid":"30914432","id":"PMC_30914432","title":"Long Noncoding RNA MALAT1 Regulates Cancer Glucose Metabolism by Enhancing mTOR-Mediated Translation of TCF7L2.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30914432","citation_count":148,"is_preprint":false},{"pmid":"18048388","id":"PMC_18048388","title":"Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer.","date":"2007","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18048388","citation_count":142,"is_preprint":false},{"pmid":"18599616","id":"PMC_18599616","title":"The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus.","date":"2008","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/18599616","citation_count":137,"is_preprint":false},{"pmid":"9916915","id":"PMC_9916915","title":"Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9916915","citation_count":131,"is_preprint":false},{"pmid":"34016596","id":"PMC_34016596","title":"The Role of TCF7L2 in Type 2 Diabetes.","date":"2021","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/34016596","citation_count":130,"is_preprint":false},{"pmid":"17416797","id":"PMC_17416797","title":"TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population.","date":"2007","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/17416797","citation_count":129,"is_preprint":false},{"pmid":"29317436","id":"PMC_29317436","title":"The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function.","date":"2018","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/29317436","citation_count":103,"is_preprint":false},{"pmid":"11711551","id":"PMC_11711551","title":"The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11711551","citation_count":102,"is_preprint":false},{"pmid":"31619789","id":"PMC_31619789","title":"Habenular TCF7L2 links nicotine addiction to diabetes.","date":"2019","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/31619789","citation_count":94,"is_preprint":false},{"pmid":"16532032","id":"PMC_16532032","title":"Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16532032","citation_count":90,"is_preprint":false},{"pmid":"9784592","id":"PMC_9784592","title":"TCF-4 binds beta-catenin and is expressed in distinct regions of the embryonic brain and limbs.","date":"1998","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/9784592","citation_count":87,"is_preprint":false},{"pmid":"27159876","id":"PMC_27159876","title":"Current Understanding on Role of the Wnt Signaling Pathway Effector TCF7L2 in Glucose Homeostasis.","date":"2016","source":"Endocrine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27159876","citation_count":87,"is_preprint":false},{"pmid":"22717537","id":"PMC_22717537","title":"Abnormal glucose tolerance and insulin secretion in pancreas-specific Tcf7l2-null mice.","date":"2012","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/22717537","citation_count":85,"is_preprint":false},{"pmid":"19602480","id":"PMC_19602480","title":"Tissue-specific alternative splicing of TCF7L2.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19602480","citation_count":83,"is_preprint":false},{"pmid":"17563454","id":"PMC_17563454","title":"The new type 2 diabetes gene TCF7L2.","date":"2007","source":"Current opinion in clinical nutrition and metabolic care","url":"https://pubmed.ncbi.nlm.nih.gov/17563454","citation_count":83,"is_preprint":false},{"pmid":"35864968","id":"PMC_35864968","title":"TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35864968","citation_count":82,"is_preprint":false},{"pmid":"31218672","id":"PMC_31218672","title":"Wnt/β-catenin signaling in brain development and mental disorders: keeping TCF7L2 in mind.","date":"2019","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/31218672","citation_count":80,"is_preprint":false},{"pmid":"16724116","id":"PMC_16724116","title":"HIC1 attenuates Wnt signaling by recruitment of TCF-4 and beta-catenin to the nuclear bodies.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16724116","citation_count":80,"is_preprint":false},{"pmid":"23028378","id":"PMC_23028378","title":"TCF7L2 modulates glucose homeostasis by regulating CREB- and FoxO1-dependent transcriptional pathway in the liver.","date":"2012","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23028378","citation_count":71,"is_preprint":false},{"pmid":"30948248","id":"PMC_30948248","title":"Targeted deletion of Tcf7l2 in adipocytes promotes adipocyte hypertrophy and impaired glucose metabolism.","date":"2019","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30948248","citation_count":69,"is_preprint":false},{"pmid":"22258766","id":"PMC_22258766","title":"SPINDLIN1 promotes cancer cell proliferation through activation of WNT/TCF-4 signaling.","date":"2012","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/22258766","citation_count":65,"is_preprint":false},{"pmid":"23142218","id":"PMC_23142218","title":"MiR-24 regulates the proliferation and invasion of glioma by ST7L via β-catenin/Tcf-4 signaling.","date":"2012","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23142218","citation_count":64,"is_preprint":false},{"pmid":"22967502","id":"PMC_22967502","title":"The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis.","date":"2012","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22967502","citation_count":64,"is_preprint":false},{"pmid":"26489464","id":"PMC_26489464","title":"Impaired LRP6-TCF7L2 Activity Enhances Smooth Muscle Cell Plasticity and Causes Coronary Artery Disease.","date":"2015","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/26489464","citation_count":62,"is_preprint":false},{"pmid":"24311645","id":"PMC_24311645","title":"TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription.","date":"2013","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24311645","citation_count":61,"is_preprint":false},{"pmid":"31632059","id":"PMC_31632059","title":"TCF-4 Regulated lncRNA-XIST Promotes M2 Polarization Of Macrophages And Is Associated With Lung Cancer.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31632059","citation_count":60,"is_preprint":false},{"pmid":"21357677","id":"PMC_21357677","title":"TCF7L2 splice variants have distinct effects on beta-cell turnover and function.","date":"2011","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21357677","citation_count":57,"is_preprint":false},{"pmid":"11454716","id":"PMC_11454716","title":"Metastasis-inducing dna regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11454716","citation_count":55,"is_preprint":false},{"pmid":"18445358","id":"PMC_18445358","title":"TCF7L2 genetic defect and type 2 diabetes.","date":"2008","source":"Current diabetes reports","url":"https://pubmed.ncbi.nlm.nih.gov/18445358","citation_count":54,"is_preprint":false},{"pmid":"25950476","id":"PMC_25950476","title":"Geniposide promotes beta-cell regeneration and survival through regulating β-catenin/TCF7L2 pathway.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/25950476","citation_count":53,"is_preprint":false},{"pmid":"32372060","id":"PMC_32372060","title":"The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32372060","citation_count":51,"is_preprint":false},{"pmid":"31736268","id":"PMC_31736268","title":"LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31736268","citation_count":50,"is_preprint":false},{"pmid":"31340839","id":"PMC_31340839","title":"KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31340839","citation_count":47,"is_preprint":false},{"pmid":"20878273","id":"PMC_20878273","title":"Molecular function of TCF7L2: Consequences of TCF7L2 splicing for molecular function and risk for type 2 diabetes.","date":"2010","source":"Current diabetes reports","url":"https://pubmed.ncbi.nlm.nih.gov/20878273","citation_count":45,"is_preprint":false},{"pmid":"29246974","id":"PMC_29246974","title":"Pancreatic Pericytes Support β-Cell Function in a Tcf7l2-Dependent Manner.","date":"2017","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/29246974","citation_count":44,"is_preprint":false},{"pmid":"26525881","id":"PMC_26525881","title":"TCF7L2 Genotype and α-Cell Function in Humans Without Diabetes.","date":"2015","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/26525881","citation_count":44,"is_preprint":false},{"pmid":"25744721","id":"PMC_25744721","title":"IKKβ Enforces a LIN28B/TCF7L2 Positive Feedback Loop That Promotes Cancer Cell Stemness and Metastasis.","date":"2015","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25744721","citation_count":44,"is_preprint":false},{"pmid":"17920061","id":"PMC_17920061","title":"Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors.","date":"2007","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/17920061","citation_count":43,"is_preprint":false},{"pmid":"24906949","id":"PMC_24906949","title":"Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin.","date":"2014","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/24906949","citation_count":43,"is_preprint":false},{"pmid":"21115178","id":"PMC_21115178","title":"Pleiotropic effects of TCF7L2 gene variants and its modulation in the metabolic syndrome: from the LIPGENE study.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21115178","citation_count":43,"is_preprint":false},{"pmid":"36797281","id":"PMC_36797281","title":"VE-Cadherin modulates β-catenin/TCF-4 to enhance Vasculogenic Mimicry.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36797281","citation_count":42,"is_preprint":false},{"pmid":"25414334","id":"PMC_25414334","title":"The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/25414334","citation_count":42,"is_preprint":false},{"pmid":"21772333","id":"PMC_21772333","title":"Wnt-β-catenin-Tcf-4 signalling-modulated invasiveness is dependent on osteopontin expression in breast cancer.","date":"2011","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21772333","citation_count":40,"is_preprint":false},{"pmid":"27181358","id":"PMC_27181358","title":"microRNA-328 inhibits cervical cancer cell proliferation and tumorigenesis by targeting TCF7L2.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27181358","citation_count":39,"is_preprint":false},{"pmid":"21720709","id":"PMC_21720709","title":"β-catenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma.","date":"2011","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21720709","citation_count":39,"is_preprint":false},{"pmid":"17768662","id":"PMC_17768662","title":"Overexpression of axin downregulates TCF-4 and inhibits the development of lung cancer.","date":"2007","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17768662","citation_count":39,"is_preprint":false},{"pmid":"33712565","id":"PMC_33712565","title":"EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33712565","citation_count":39,"is_preprint":false},{"pmid":"34265237","id":"PMC_34265237","title":"Regulatory variants in TCF7L2 are associated with thoracic aortic aneurysm.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34265237","citation_count":38,"is_preprint":false},{"pmid":"34612510","id":"PMC_34612510","title":"The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetes.","date":"2021","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34612510","citation_count":36,"is_preprint":false},{"pmid":"22945304","id":"PMC_22945304","title":"TCF7L2 promotes beta cell regeneration in human and mouse pancreas.","date":"2012","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/22945304","citation_count":36,"is_preprint":false},{"pmid":"32675279","id":"PMC_32675279","title":"TCF7L2 regulates postmitotic differentiation programmes and excitability patterns in the thalamus.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32675279","citation_count":35,"is_preprint":false},{"pmid":"33277756","id":"PMC_33277756","title":"Circ-PRMT5 promotes breast cancer by the miR-509-3p/TCF7L2 axis activating the PI3K/AKT pathway.","date":"2020","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33277756","citation_count":35,"is_preprint":false},{"pmid":"29916101","id":"PMC_29916101","title":"RUNX3 inhibits glioma survival and invasion via suppression of the β-catenin/TCF-4 signaling pathway.","date":"2018","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29916101","citation_count":34,"is_preprint":false},{"pmid":"29751817","id":"PMC_29751817","title":"Tcf7L2 is essential for neurogenesis in the developing mouse neocortex.","date":"2018","source":"Neural development","url":"https://pubmed.ncbi.nlm.nih.gov/29751817","citation_count":34,"is_preprint":false},{"pmid":"22160878","id":"PMC_22160878","title":"Tcf7l2 is tightly controlled during myelin formation.","date":"2011","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22160878","citation_count":34,"is_preprint":false},{"pmid":"37798419","id":"PMC_37798419","title":"Astrocytic β-catenin signaling via TCF7L2 regulates synapse development and social behavior.","date":"2023","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/37798419","citation_count":33,"is_preprint":false},{"pmid":"19789636","id":"PMC_19789636","title":"Alternative splicing of TCF7L2 gene in omental and subcutaneous adipose tissue and risk of type 2 diabetes.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19789636","citation_count":33,"is_preprint":false},{"pmid":"27742678","id":"PMC_27742678","title":"MiR-181a-5p regulates 3T3-L1 cell adipogenesis by targeting Smad7 and Tcf7l2.","date":"2016","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/27742678","citation_count":32,"is_preprint":false},{"pmid":"33452226","id":"PMC_33452226","title":"The Wnt Effector TCF7l2 Promotes Oligodendroglial Differentiation by Repressing Autocrine BMP4-Mediated Signaling.","date":"2021","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33452226","citation_count":32,"is_preprint":false},{"pmid":"24151146","id":"PMC_24151146","title":"Reg4-induced mitogenesis involves Akt-GSK3β-β-Catenin-TCF-4 signaling in human colorectal cancer.","date":"2013","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24151146","citation_count":32,"is_preprint":false},{"pmid":"27058589","id":"PMC_27058589","title":"Transcription Factor 7-Like 2 (TCF7L2) rs7903146 Polymorphism as a Risk Factor for Gestational Diabetes Mellitus: A Meta-Analysis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27058589","citation_count":31,"is_preprint":false},{"pmid":"16204248","id":"PMC_16204248","title":"TIS7 regulation of the beta-catenin/Tcf-4 target gene osteopontin (OPN) is histone deacetylase-dependent.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16204248","citation_count":29,"is_preprint":false},{"pmid":"23029137","id":"PMC_23029137","title":"Inhibition of Tcf-4 induces apoptosis and enhances chemosensitivity of colon cancer cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029137","citation_count":28,"is_preprint":false},{"pmid":"33068125","id":"PMC_33068125","title":"Adipocyte-specific deletion of Tcf7l2 induces dysregulated lipid metabolism and impairs glucose tolerance in mice.","date":"2020","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/33068125","citation_count":27,"is_preprint":false},{"pmid":"28002648","id":"PMC_28002648","title":"Association between TCF7L2 polymorphisms and gestational diabetes mellitus: A meta-analysis.","date":"2017","source":"Journal of diabetes investigation","url":"https://pubmed.ncbi.nlm.nih.gov/28002648","citation_count":26,"is_preprint":false},{"pmid":"32739175","id":"PMC_32739175","title":"Artesunate inhibits atherosclerosis by upregulating vascular smooth muscle cells-derived LPL expression via the KLF2/NRF2/TCF7L2 pathway.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32739175","citation_count":25,"is_preprint":false},{"pmid":"35841271","id":"PMC_35841271","title":"TCF7l2, a nuclear marker that labels premyelinating oligodendrocytes and promotes oligodendroglial lineage progression.","date":"2022","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/35841271","citation_count":24,"is_preprint":false},{"pmid":"19845015","id":"PMC_19845015","title":"Expression of the diabetes-associated gene TCF7L2 in adult mouse brain.","date":"2009","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19845015","citation_count":24,"is_preprint":false},{"pmid":"34568447","id":"PMC_34568447","title":"Transcription Factor-7-Like-2 (TCF7L2) in Atherosclerosis: A Potential Biomarker and Therapeutic Target.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34568447","citation_count":24,"is_preprint":false},{"pmid":"23977356","id":"PMC_23977356","title":"Limited TCF7L2 expression in MS lesions.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23977356","citation_count":24,"is_preprint":false},{"pmid":"27430592","id":"PMC_27430592","title":"Gastrin promotes the metastasis of gastric carcinoma through the β-catenin/TCF-4 pathway.","date":"2016","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/27430592","citation_count":24,"is_preprint":false},{"pmid":"23951231","id":"PMC_23951231","title":"Association between TCF7L2 gene polymorphism and cancer risk: a meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23951231","citation_count":23,"is_preprint":false},{"pmid":"31312258","id":"PMC_31312258","title":"TCF7L2 regulates pancreatic β-cell function through PI3K/AKT signal pathway.","date":"2019","source":"Diabetology & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/31312258","citation_count":23,"is_preprint":false},{"pmid":"34535768","id":"PMC_34535768","title":"TCF7L2 lncRNA: a link between bipolar disorder and body mass index through glucocorticoid signaling.","date":"2021","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/34535768","citation_count":23,"is_preprint":false},{"pmid":"36044851","id":"PMC_36044851","title":"A TCF7L2-responsive suppression of both homeostatic and compensatory remyelination in Huntington disease mice.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36044851","citation_count":21,"is_preprint":false},{"pmid":"26102344","id":"PMC_26102344","title":"Polymorphisms in FTO and TCF7L2 genes of Euro-Brazilian women with gestational diabetes.","date":"2015","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26102344","citation_count":21,"is_preprint":false},{"pmid":"23579632","id":"PMC_23579632","title":"Association of rs12255372 in the TCF7L2 gene with type 2 diabetes mellitus: a meta-analysis.","date":"2013","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/23579632","citation_count":20,"is_preprint":false},{"pmid":"15547706","id":"PMC_15547706","title":"Differential expression and splicing isoform analysis of human Tcf-4 transcription factor in brain tumors.","date":"2004","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/15547706","citation_count":19,"is_preprint":false},{"pmid":"20171202","id":"PMC_20171202","title":"En2, Pax2/5 and Tcf-4 transcription factors cooperate in patterning the Xenopus brain.","date":"2010","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20171202","citation_count":19,"is_preprint":false},{"pmid":"29312594","id":"PMC_29312594","title":"Investigation of TCF7L2, LEP and LEPR polymorphisms with esophageal squamous cell carcinomas.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29312594","citation_count":19,"is_preprint":false},{"pmid":"29736187","id":"PMC_29736187","title":"TCF7L2 correlation in both insulin secretion and postprandial insulin sensitivity.","date":"2018","source":"Diabetology & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/29736187","citation_count":19,"is_preprint":false},{"pmid":"28949031","id":"PMC_28949031","title":"Cumulative evidence for relationships between multiple variants in the VTI1A and TCF7L2 genes and cancer incidence.","date":"2017","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28949031","citation_count":18,"is_preprint":false},{"pmid":"34753394","id":"PMC_34753394","title":"MicroRNA-22-3p targeted regulating transcription factor 7-like 2 (TCF7L2) constrains the Wnt/β-catenin pathway and malignant behavior in osteosarcoma.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34753394","citation_count":18,"is_preprint":false},{"pmid":"31470081","id":"PMC_31470081","title":"A meta-analysis on associations of FTO, MTHFR and TCF7L2 polymorphisms with polycystic ovary syndrome.","date":"2019","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31470081","citation_count":18,"is_preprint":false},{"pmid":"17683561","id":"PMC_17683561","title":"The TCF7L2 locus and type 1 diabetes.","date":"2007","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17683561","citation_count":17,"is_preprint":false},{"pmid":"30647622","id":"PMC_30647622","title":"Common variants in TCF7L2 and CDKAL1 genes and risk of type 2 diabetes mellitus in Egyptians.","date":"2016","source":"Journal, genetic engineering & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30647622","citation_count":17,"is_preprint":false},{"pmid":"27465520","id":"PMC_27465520","title":"Polymorphisms in TCF7L2 gene are associated with gestational diabetes mellitus in Chinese Han population.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27465520","citation_count":17,"is_preprint":false},{"pmid":"30557604","id":"PMC_30557604","title":"TCF7L2 and EGR1 synergistic activation of transcription of LCN2 via an ERK1/2-dependent pathway in esophageal squamous cell carcinoma cells.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30557604","citation_count":17,"is_preprint":false},{"pmid":"38390305","id":"PMC_38390305","title":"HIF2α Promotes Cancer Metastasis through TCF7L2-Dependent Fatty Acid Synthesis in ccRCC.","date":"2024","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/38390305","citation_count":16,"is_preprint":false},{"pmid":"35691375","id":"PMC_35691375","title":"TCF7L2 promotes ER stress signaling in diabetic retinopathy.","date":"2022","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/35691375","citation_count":16,"is_preprint":false},{"pmid":"27108846","id":"PMC_27108846","title":"TCF7L2 involvement in estradiol- and progesterone-modulated islet and hepatic glucose homeostasis.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27108846","citation_count":16,"is_preprint":false},{"pmid":"28343277","id":"PMC_28343277","title":"Pancreatic alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion and counter-regulatory responses to hypoglycaemia in mice.","date":"2017","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/28343277","citation_count":16,"is_preprint":false},{"pmid":"27793772","id":"PMC_27793772","title":"TCF7L2 mediates the cellular and behavioral response to chronic lithium treatment in animal models.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27793772","citation_count":16,"is_preprint":false},{"pmid":"30467975","id":"PMC_30467975","title":"ADIPOQ, KCNJ11 and TCF7L2 polymorphisms in type 2 diabetes in Kyrgyz population: A case-control study.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30467975","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53963,"output_tokens":8583,"usd":0.145317,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18615,"output_tokens":8291,"usd":0.150175,"stage2_stop_reason":"end_turn"},"total_usd":0.295492,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"The β-catenin/TCF-4 complex controls proliferation versus differentiation in intestinal epithelial cells by directly repressing p21(CIP1/WAF1) transcription through c-MYC; disruption of β-catenin/TCF-4 activity decreases c-MYC expression, releases p21(CIP1/WAF1) transcription, and induces G1 arrest and differentiation.\",\n      \"method\": \"Dominant-negative TCF-4 expression in CRC cell lines, reporter assays, gene expression analysis, loss-of-function experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean loss-of-function with defined mechanistic pathway (TCF-4→c-MYC→p21→G1 arrest), replicated across multiple CRC cell lines with multiple orthogonal readouts\",\n      \"pmids\": [\"12408868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TCF-4 contains distinct binding sites for β-catenin (N-terminal first 50 amino acids) and plakoglobin (residues 51–80); CK2 phosphorylates Tcf-4 at Ser-58/59/60, reducing plakoglobin binding without affecting β-catenin binding; plakoglobin binding to TCF-4 negatively affects TCF-4 transcriptional activity.\",\n      \"method\": \"In vitro kinase assay with CK2, deletion mapping/pulldown, co-immunoprecipitation, ternary complex reconstitution, TCF-4 mutant transcriptional activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution, mutagenesis, and binding domain mapping in a single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"11711551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"HIC1 antagonizes TCF/β-catenin-mediated transcription by physically associating with TCF-4 and recruiting TCF-4 and β-catenin to HIC1 nuclear bodies, preventing their association with TCF-binding elements of Wnt-responsive genes.\",\n      \"method\": \"Co-immunoprecipitation, nuclear body co-localization imaging, reporter assays (TOPflash), loss-of-function in Wnt-stimulated cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, live imaging of nuclear bodies, and functional reporter assay in one study with multiple orthogonal methods\",\n      \"pmids\": [\"16724116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TCF-4 protein is highly and restrictedly expressed in intestinal crypt epithelium and mammary gland epithelium, with a temporal expression gradient along the crypt-villus axis (high in crypts, low on villi in early fetal intestine), consistent with its role in proliferative compartment maintenance.\",\n      \"method\": \"Immunohistochemistry with TCF-4-specific monoclonal antibodies on mouse and human tissues\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by IHC with tissue-specific antibodies, replicated in multiple tissue types and developmental stages; no direct functional consequence tested in this paper\",\n      \"pmids\": [\"9916915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TCF-4 binds β-catenin and induces nuclear localization of β-catenin in expressing cells; two isoforms of mouse Tcf-4 are expressed in distinct regions of the embryonic CNS (hindbrain, diencephalon) and limb bud mesenchyme; Tcf-4 expression in the forebrain requires Pax-6.\",\n      \"method\": \"Co-immunoprecipitation of TCF-4 with β-catenin, in situ hybridization, Small eye mutant analysis (epistasis)\",\n      \"journal\": \"Mechanisms of development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP binding demonstrated, genetic epistasis (Pax6 required for Tcf-4 forebrain expression), and spatial expression in defined developmental contexts\",\n      \"pmids\": [\"9784592\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TCF-4 acts as a transcriptional repressor of the osteopontin (OPN) promoter; metastasis-inducing DNA containing CAAAG Tcf recognition sequences sequesters endogenous inhibitory TCF-4, thereby de-repressing OPN transcription and promoting metastasis.\",\n      \"method\": \"EMSA with cell extracts, Western blot identification of TCF-4/β-catenin/E-cadherin in DNA complexes, cotransfection of TCF-4 expression vector with OPN promoter-reporter construct, stable transfection, in vivo metastasis assay in syngeneic rats\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — EMSA, reporter assay, expression vector rescue, and in vivo functional validation in one study with multiple orthogonal methods\",\n      \"pmids\": [\"11454716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Reduced TCF7L2 (Tcf-4) expression in ileal Crohn's disease correlates with decreased α-defensin expression; quantitative binding analysis shows reduced TCF7L2 binding activity at HD-5 and HD-6 promoters in ileal CD biopsies; heterozygous Tcf-4 (+/-) mice show significantly decreased Paneth cell α-defensin levels and bacterial killing activity, establishing Tcf-4 as a causal regulator of Paneth cell α-defensin expression.\",\n      \"method\": \"Quantitative nuclear extract binding assay, murine Tcf-4 heterozygous knockout model, bacterial killing assay, quantitative RT-PCR\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding assay, heterozygous KO mouse model with specific antimicrobial phenotype, multiple orthogonal methods in one study\",\n      \"pmids\": [\"17709525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TCF7l2 protein is expressed specifically during active remyelination (not developmental myelination) in non-dividing oligodendrocyte precursors; TCF7l2 forms a protein complex with Olig2 but not Olig1 in the context of myelin formation.\",\n      \"method\": \"Co-immunoprecipitation (TCF7l2-Olig2 complex), demyelination/remyelination mouse model (dietary cuprizone), immunofluorescence, Western blot\",\n      \"journal\": \"Cellular and molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP demonstrating specific Olig2 (not Olig1) interaction, in vivo remyelination model with temporal protein expression analysis\",\n      \"pmids\": [\"22160878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Pancreas-specific deletion of Tcf7l2 impairs glucose-stimulated insulin secretion and GLP-1 response in isolated islets, reduces Glp1r and Ins2 expression, and impairs beta cell mass expansion on high-fat diet, demonstrating a direct role for TCF7L2 in beta cell function.\",\n      \"method\": \"Conditional knockout (Pdx1-Cre × Tcf7l2-flox), glucose tolerance tests, isolated islet insulin secretion assays, optical projection tomography for beta cell mass, quantitative PCR\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific cellular phenotype, multiple orthogonal readouts (GSIS, GLP-1 response, mass, gene expression) in one study\",\n      \"pmids\": [\"22717537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TCF7L2 binds to promoters of gluconeogenic genes (including PEPCK pathway) and inhibits adjacent promoter occupancy by CREB, CRTC2, and FoxO1; hepatic TCF7L2 knockdown increases gluconeogenic gene expression and blood glucose, while overexpression of a nuclear TCF7L2 isoform ameliorates hyperglycemia in high-fat diet mice.\",\n      \"method\": \"ChIP (TCF7L2 binding to gluconeogenic promoters), siRNA knockdown, adenoviral overexpression, CREB/FoxO1 promoter occupancy assay, in vivo glucose tolerance tests\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP demonstrating direct promoter binding, epistatic analysis with CREB/FoxO1, in vivo rescue experiments with multiple orthogonal methods\",\n      \"pmids\": [\"23028378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Insulin upregulates hepatic TCF7L2 expression and stimulates β-catenin Ser675 phosphorylation; TCF7L2 knockdown by siRNA increases hepatic glucose production and gluconeogenic gene expression, identifying TCF7L2 as a downstream effector of insulin signaling that represses hepatic gluconeogenesis.\",\n      \"method\": \"siRNA knockdown in hepatocytes, in vivo lithium injection (Wnt activation), TOPGAL transgenic mouse hepatic Wnt activity assay, Western blot for β-catenin Ser675 phosphorylation, glucose production assay\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with specific functional readout, in vivo Wnt activation, phosphorylation assay; single lab\",\n      \"pmids\": [\"22967502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TCF7L2 regulates a transcriptional network in pancreatic islets in which ISL1 is a primary direct target; ISL1 in turn regulates proinsulin production and processing via MAFA, PDX1, NKX6.1, PCSK1, PCSK2, and SLC30A8; the T2D risk allele of rs7903146 is associated with increased TCF7L2 expression and decreased insulin content and secretion.\",\n      \"method\": \"RNA-sequencing of rodent and human islets with TCF7L2 manipulation, human islet gene expression profiles from 66 donors genotyped for rs7903146\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq with genotype-stratified analysis in human islets; pathway assignment supported by multiple targets; single lab\",\n      \"pmids\": [\"25015099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"In hepatoma cells, TCF7L2 directly regulates 149 target genes (by ChIP-seq proximal binding) including key regulators of glucose, lipid, and amino acid metabolism; TCF7L2 silencing enhances HNF4α expression and chromatin occupancy, and HNF4α is required for TCF7L2-mediated regulation of a subset of metabolic genes.\",\n      \"method\": \"ChIP-seq (TCF7L2 binding genome-wide), RNA-seq (time-course after Tcf7l2 silencing), co-siRNA epistasis experiments for HNF4α\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP-seq + RNA-seq + epistasis (co-siRNA) in one study with multiple orthogonal methods establishing genome-wide direct regulatory targets and mechanistic interplay with HNF4α\",\n      \"pmids\": [\"25414334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Impaired LRP6 activity in LRP6(R611C) mice leads to diminished TCF7L2 activity and increased Sp1-dependent PDGF signaling, promoting loss of VSMC differentiation; Wnt3a administration restores TCF7L2-dependent VSMC differentiation and rescues post-carotid-injury neointima formation.\",\n      \"method\": \"LRP6(R611C) knock-in mouse model, carotid injury model, Wnt3a administration rescue, molecular analysis of PDGF/TCF7L2/Sp1 pathway\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic model with rescue experiment, pathway mechanistic dissection; single lab\",\n      \"pmids\": [\"26489464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Tcf7l2 activity in pancreatic pericytes is required for β-cell function; pericyte-specific Tcf7l2 inactivation impairs glucose tolerance and glucose-stimulated insulin secretion; Tcf7l2-dependent pericytic expression of secreted factors including BMP4 supports β-cell function, and exogenous BMP4 rescues impaired insulin secretion.\",\n      \"method\": \"Pericyte-specific Tcf7l2 conditional knockout mice, glucose tolerance tests, isolated islet GSIS, BMP4 rescue experiment, gene expression analysis\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined functional rescue (BMP4), multiple phenotypic readouts, identifies a paracrine mechanism\",\n      \"pmids\": [\"29246974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Alpha cell-selective deletion of Tcf7l2 impairs glucagon secretion at low glucose, reduces alpha cell mass, and increases glucose infusion rates during hypoglycaemic clamp, demonstrating a cell-autonomous role for TCF7L2 in pancreatic alpha cell function and counter-regulatory responses.\",\n      \"method\": \"Alpha cell-selective Tcf7l2 KO (PPGCre × Tcf7l2-flox), hyperinsulinaemic-hypoglycaemic clamp, isolated islet glucagon secretion assay\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with specific physiological phenotype, clamp assay and ex vivo islet studies, multiple orthogonal readouts\",\n      \"pmids\": [\"28343277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TCF7L2 protein is required for regulation of Wnt signaling during adipogenesis; TCF7L2 expression increases during adipogenesis in 3T3-L1 cells; inactivation of TCF7L2's HMG-box DNA-binding domain in mature adipocytes in vivo leads to whole-body glucose intolerance, hepatic insulin resistance, subcutaneous adipose hypertrophy, and inflammation.\",\n      \"method\": \"In vitro adipogenesis assays (3T3-L1 and primary adipocyte stem cells), adipocyte-specific TCF7L2 HMG-box deletion mouse model, glucose tolerance tests, ChIP-seq and RNA-seq in adipocytes\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — HMG-box domain deletion (functional mutagenesis), in vivo adipocyte-specific KO, ChIP-seq genome-wide binding, multiple orthogonal methods\",\n      \"pmids\": [\"29317436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Adipocyte-specific deletion of Tcf7l2 leads to adipocyte hypertrophy, impaired glucose tolerance, insulin resistance, reduced triglyceride hydrolase expression, and impaired fasting-induced free fatty acid release; ChIP-seq shows TCF7L2 directly binds and regulates genes involved in lipid and glucose metabolism in adipocytes.\",\n      \"method\": \"Adipocyte-specific Tcf7l2 KO mouse (Adipoq-Cre), high-fat diet challenge, ChIP-seq, RNA-seq, lipolysis assay, glucose/insulin tolerance tests\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — adipocyte-specific KO with ChIP-seq and RNA-seq, multiple metabolic phenotypic readouts\",\n      \"pmids\": [\"30948248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MALAT1 enhances TCF7L2 mRNA translation via upregulation of SRSF1 and activation of the mTORC1-4EBP1 axis; MALAT1 increases TCF7L2 mRNA association with heavy polysomes likely through the TCF7L2 5′UTR; knockdown of TCF7L2 abolishes MALAT1's effects on glucose metabolism and tumorigenicity.\",\n      \"method\": \"Polysome fractionation, 5′UTR-reporter assays, pharmacological/genetic mTOR inhibition, hypophosphorylated 4EBP1 mutant expression, siRNA knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — polysome fractionation and 5′UTR reporter assays with mTOR inhibition and epistasis; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30914432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TCF7L2 is densely expressed in the medial habenula (mHb) and regulates nicotinic acetylcholine receptor function there; inhibition of TCF7L2 signaling in the mHb increases nicotine intake; nicotine increases blood glucose via TCF7L2-dependent stimulation of the mHb; virus tracing identifies a polysynaptic mHb-to-pancreas connection; mutant Tcf7l2 rats are resistant to nicotine-induced blood glucose dysregulation.\",\n      \"method\": \"Viral TCF7L2 inhibition in the mHb, nicotine self-administration assay, anterograde/retrograde viral tracing, Tcf7l2 mutant rat model, blood glucose and glucagon/insulin measurements\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo methods (viral inhibition, mutant rat, circuit tracing), functional rescue/genetic resistance, published in high-impact journal\",\n      \"pmids\": [\"31619789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TCF7L2 regulates postmitotic differentiation programmes in the thalamus, functioning as a thalamic terminal selector; loss of Tcf7l2 disrupts thalamo-habenular connectivity, regional transcription factor expression, cell migration/axon guidance genes, and impairs terminal electrophysiological features (firing modes) of thalamic neurons; many of these genes are direct TCF7L2 targets.\",\n      \"method\": \"Complete and conditional Tcf7l2 knockout mice, postnatal Tcf7l2 KO, electrophysiology, ChIP for direct target identification, RNA-seq\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple KO models (embryonic and postnatal conditional), electrophysiology, ChIP for direct targets, multiple orthogonal methods\",\n      \"pmids\": [\"32675279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TCF7L2 directly represses BMP4 transcription by binding to the Bmp4 gene regulatory element in oligodendrocytes; disruption of TCF7l2 in mice causes oligodendroglial BMP4 upregulation and canonical BMP4 signaling activation; enforced TCF7l2 expression promotes oligodendrocyte differentiation by reducing autocrine BMP4 secretion; compound genetic deletion of oligodendroglial BMP4 rescues arrested OL differentiation caused by TCF7l2 disruption.\",\n      \"method\": \"Tcf7l2 conditional KO in oligodendrocytes, BMP4 conditional KO (compound genetics/epistasis), ChIP (TCF7l2 binding to Bmp4 regulatory element), in vitro OL differentiation assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP demonstrating direct Bmp4 binding, compound genetic rescue (epistasis), multiple in vivo and in vitro readouts, mechanistically rigorous\",\n      \"pmids\": [\"33452226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TCF7L2 mediates thalamic-specific nuclear translocation of β-catenin in response to lithium; silencing Tcf7l2 in thalamic neurons prevents β-catenin from entering the nucleus even under lithium treatment; ectopic Tcf7l2 expression in cortical neurons shifts β-catenin to the nucleus; Tcf7l2 knockdown in zebrafish abolishes lithium's behavioral effects.\",\n      \"method\": \"Lentiviral Tcf7l2 silencing in thalamic neurons, ectopic Tcf7l2 expression in cortical neurons, nuclear fractionation, immunofluorescence, zebrafish tcf7l2 knockdown behavioral assay\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific silencing and ectopic expression with nuclear fractionation, in vivo zebrafish behavioral epistasis; single lab\",\n      \"pmids\": [\"27793772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TCF7L2 is the dominant Wnt effector in postnatal astrocytes; conditional Tcf7l2 KO in postnatal astrocytes enlarges astrocytes, disrupts tiling and gap junction coupling, increases cortical excitatory and inhibitory synapse numbers, and increases adult social interaction, demonstrating a cell-autonomous role for TCF7L2-dependent Wnt/β-catenin signaling in astrocyte maturation and synapse number restriction.\",\n      \"method\": \"Postnatal astrocyte-specific Tcf7l2 conditional KO mice, astrocyte morphology and tiling analysis, gap junction coupling assay, synapse quantification, behavioral testing\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — astrocyte-specific KO with defined cellular (tiling, gap junctions) and circuit (synapse numbers) phenotypes plus behavioral readout, multiple orthogonal methods\",\n      \"pmids\": [\"37798419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TIS7 downregulates β-catenin/TCF-4 transcriptional activity through interaction with histone deacetylase-containing complexes; TIS7 overexpression leads to β-catenin interaction with enzymatically active histone deacetylases; TIS7 homologous deletion in mouse embryonic fibroblasts increases TOPflash reporter activity and expression of c-Myc and OPN.\",\n      \"method\": \"TOPflash reporter assay, co-immunoprecipitation with histone deacetylases, TIS7 knockout MEFs, TIS7 overexpression, gene expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with enzymatically active HDAC complex, KO and OE functional data, reporter assay; single lab with multiple methods\",\n      \"pmids\": [\"16204248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TCF7L2 splice variants have distinct effects on β-cell survival and function: clone B1 (lacking exons 13–16) induces β-cell apoptosis, impairs function, and inhibits Wnt signaling, while clones B3 and B7 (containing exon 13) improve β-cell survival and function and activate Wnt signaling; TCF7L2 depletion activates GSK3β independently of ER stress.\",\n      \"method\": \"TCF7L2 splice variant overexpression and knockdown in human isolated islets, apoptosis assays, GSIS, TOPflash/FOPflash reporter assay, GSK3β activity measurement\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific functional dissection in primary human islets with multiple orthogonal readouts; single lab\",\n      \"pmids\": [\"21357677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TCF7L2 overexpression in isolated exocrine cells induces duct cell proliferation and islet-like cell cluster (ICC) formation in a JAK2/STAT3-dependent manner, suggesting a role for TCF7L2 in beta cell regeneration from ductal epithelium.\",\n      \"method\": \"Adenoviral TCF7L2 overexpression in isolated exocrine cells, JAK2/STAT3 pathway inhibition, quantification of ICC formation, in vivo high-fat diet and streptozotocin mouse models\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct overexpression with pathway inhibition (JAK2/STAT3 epistasis), in vivo corroborative models; single lab\",\n      \"pmids\": [\"22945304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TCF7L2 binds directly to the PIK3R1 promoter at evolutionarily conserved TCF7L2-binding motifs and inhibits PIK3R1/PI3K p85 expression, thereby activating PI3K/AKT signaling and stimulating insulin secretion in pancreatic β-cells.\",\n      \"method\": \"ChIP-PCR, luciferase reporter assay, lentiviral TCF7L2 knockdown/overexpression, Western blot for PI3K p85 and p-AKT, ELISA for insulin secretion\",\n      \"journal\": \"Diabetology & metabolic syndrome\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, reporter assay, gain/loss-of-function with functional insulin secretion readout; single lab\",\n      \"pmids\": [\"31312258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TCF7L2 and EGR1 synergistically activate LCN2 transcription by directly binding to their respective sites within the LCN2 promoter (-273/-209 for TCF7L2; -710/-616 for EGR1) via the ERK signaling pathway; recombinant LCN2 further enhances ERK activation and TCF7L2/EGR1 expression in a positive feedback loop.\",\n      \"method\": \"ChIP, luciferase reporter with deletion mapping, MEK inhibitor (U0126) epistasis, overexpression and knockdown, migration/invasion assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP demonstrating direct TCF7L2 promoter binding, deletion mapping, pathway epistasis (MEK inhibitor); single lab with multiple orthogonal methods\",\n      \"pmids\": [\"30557604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In a Huntington's disease mouse model, TCF7L2-dependent transcription is repressed; in vivo Tcf7l2 overexpression restores myelin gene expression and remyelination in demyelinated R6/2 mice, causally linking impaired TCF7L2-dependent transcription to poor myelination in HD.\",\n      \"method\": \"RNA-sequencing of HD mouse callosal white matter and OPCs, proteomic analysis, in vivo Tcf7l2 overexpression (viral vector) in R6/2 mice, cuprizone demyelination/remyelination assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo gene overexpression rescue in disease model, transcriptomic and proteomic network analysis; single lab\",\n      \"pmids\": [\"36044851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Upregulation of TCF7L2 in vascular smooth muscle cells is associated with BCL2 repression and promotes VSMC apoptosis, which is a potential driver of thoracic aortic aneurysm; the TAA genetic association at the TCF7L2 locus colocalizes with an aortic eQTL of TCF7L2.\",\n      \"method\": \"In vitro TCF7L2 upregulation experiment in VSMCs, BCL2 expression assay, eQTL colocalization analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — in vitro overexpression with single molecular readout (BCL2); broader claim rests on eQTL colocalization; limited mechanistic depth\",\n      \"pmids\": [\"34265237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Adipocyte-specific Tcf7l2 deletion leads to impaired glucose tolerance, increased fat mass, reduced incretin (GLP-1 and GIP) levels, and increased circulating NEFA and FABP4, with a sexually dimorphic phenotype (males only), suggesting TCF7L2 in adipocytes regulates pancreatic islet and enteroendocrine cell function via paracrine/endocrine mechanisms.\",\n      \"method\": \"Adipoq-Cre × Tcf7l2-flox conditional KO mice, normal chow and high-fat diet challenge, in vitro GSIS, incretin measurements, NEFA and FABP4 plasma assays\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with multiple hormonal and metabolic readouts; proposed paracrine mechanism is inferred but not directly demonstrated; single lab\",\n      \"pmids\": [\"33068125\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TCF7L2 (TCF-4) is a HMG-box transcription factor that forms a bipartite complex with β-catenin to serve as the principal nuclear effector of canonical Wnt signaling; it directly binds TCF/LEF response elements to activate or repress target genes (including c-MYC, p21, OPN, BMP4, PIK3R1, gluconeogenic genes, LCN2, and Paneth cell α-defensins), interacts with co-regulators including plakoglobin (at a distinct N-terminal site phosphorylated by CK2), HIC1 (which sequesters it to nuclear bodies), Olig2, and histone deacetylase complexes; it controls intestinal crypt proliferation versus differentiation, pancreatic beta- and alpha-cell function (insulin and glucagon secretion), hepatic gluconeogenesis (by blocking CREB/FoxO1 promoter occupancy), adipocyte metabolism, oligodendrocyte differentiation (by directly repressing BMP4), thalamic neuronal terminal differentiation, astrocyte maturation and synapse number restriction, and habenular regulation of a brain-pancreas axis linking nicotine to glucose homeostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TCF7L2 (TCF-4) is an HMG-box transcription factor that serves as the principal nuclear effector of canonical Wnt signaling, binding β-catenin through its N-terminal first 50 residues and directing transcriptional activation or repression of target genes that govern proliferation, differentiation, and metabolism [#1, #4]. Its co-regulatory output is tuned by competing partners: plakoglobin binds an adjacent N-terminal site (residues 51–80) and dampens activity in a manner controlled by CK2 phosphorylation at Ser-58/59/60 [#1], HIC1 sequesters TCF-4/β-catenin into nuclear bodies away from Wnt-responsive elements [#2], and TIS7 recruits histone deacetylase complexes to repress TCF-4 output [#24]. In the intestine, TCF-4 maintains the proliferative crypt compartment by repressing p21(CIP1/WAF1) through c-MYC, and its disruption triggers G1 arrest and differentiation [#0, #3]; it also drives Paneth cell α-defensin expression, with reduced binding underlying diminished antimicrobial output in ileal Crohn's disease [#6]. Genome-wide, TCF7L2 directly binds and regulates large programs of glucose, lipid, and amino acid metabolic genes, acting through interplay with HNF4α in liver [#12] and across adipocytes where loss of its HMG-box DNA-binding function produces glucose intolerance, insulin resistance, and adipocyte hypertrophy [#16, #17]. In the pancreas it controls β-cell insulin secretion and mass via an ISL1-centered network and by repressing PIK3R1 to activate PI3K/AKT [#8, #11, #27], supports α-cell glucagon secretion and counter-regulation [#15], and acts non-cell-autonomously through pericytic BMP4 [#14]; in liver it represses gluconeogenesis downstream of insulin by blocking CREB/CRTC2/FoxO1 promoter occupancy [#9, #10]. In the nervous system TCF7L2 functions as a thalamic terminal selector [#20], drives astrocyte maturation and synapse-number restriction [#23], promotes oligodendrocyte differentiation by directly repressing BMP4 [#21], and in the medial habenula links nicotine to glucose homeostasis through a polysynaptic brain-pancreas circuit [#19].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that TCF-4 physically binds β-catenin and drives its nuclear localization, placing TCF-4 as a Wnt pathway transcriptional partner with spatially defined developmental expression.\",\n      \"evidence\": \"Co-IP of TCF-4 with β-catenin, in situ hybridization, and Pax-6 epistasis in mouse embryos\",\n      \"pmids\": [\"9784592\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct target genes not defined\", \"Functional consequence of nuclear β-catenin recruitment not tested in this study\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Localized TCF-4 protein to the proliferative crypt and mammary epithelium with a crypt-villus gradient, anchoring its inferred role in proliferative compartment maintenance.\",\n      \"evidence\": \"IHC with TCF-4-specific monoclonal antibodies on mouse and human tissue\",\n      \"pmids\": [\"9916915\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional perturbation in this study\", \"Does not establish which target genes drive the proliferative role\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the bipartite N-terminal architecture of TCF-4 and its phospho-regulation, showing β-catenin and plakoglobin bind distinct sites and CK2 phosphorylation selectively reduces inhibitory plakoglobin binding.\",\n      \"evidence\": \"In vitro CK2 kinase assay, deletion mapping, Co-IP, ternary complex reconstitution, and mutant transcriptional assays\",\n      \"pmids\": [\"11711551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of CK2 phosphorylation not established\", \"Effect on specific endogenous target genes not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated TCF-4 can act as a direct transcriptional repressor (of osteopontin) and that DNA decoy sequences titrating endogenous TCF-4 de-repress targets to promote metastasis, showing context-dependent repressive output.\",\n      \"evidence\": \"EMSA, OPN promoter-reporter cotransfection, and in vivo syngeneic rat metastasis assay\",\n      \"pmids\": [\"11454716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-regulator partners mediating repression not defined here\", \"Generalizability across promoters not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Defined the core intestinal mechanism: β-catenin/TCF-4 maintains proliferation by repressing p21 via c-MYC, and its loss drives G1 arrest and differentiation.\",\n      \"evidence\": \"Dominant-negative TCF-4 in CRC lines with reporter and expression analyses\",\n      \"pmids\": [\"12408868\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address normal homeostatic crypt dynamics in vivo\", \"Other downstream targets contributing to differentiation not enumerated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified a negative regulatory mechanism in which HIC1 sequesters TCF-4/β-catenin into nuclear bodies, spatially uncoupling the complex from Wnt-responsive promoters.\",\n      \"evidence\": \"Reciprocal Co-IP, nuclear body co-localization imaging, and TOPflash reporter assays\",\n      \"pmids\": [\"16724116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of sequestration unresolved\", \"Physiological contexts where HIC1 controls TCF-4 not mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed TCF-4 output is repressed by TIS7-mediated recruitment of HDAC complexes, providing a chromatin-modifying brake on β-catenin/TCF-4 transcription.\",\n      \"evidence\": \"TOPflash assay, Co-IP with active HDACs, and TIS7 KO MEF gene expression analysis\",\n      \"pmids\": [\"16204248\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect TIS7-TCF-4 contact not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established TCF7L2 as a causal regulator of Paneth cell α-defensin expression, linking reduced TCF7L2 binding to impaired antimicrobial defense in ileal Crohn's disease.\",\n      \"evidence\": \"Quantitative promoter binding assay, Tcf-4 heterozygous KO mice, and bacterial killing assays\",\n      \"pmids\": [\"17709525\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the human disease association is causal or correlative not settled\", \"Direct defensin promoter occupancy in vivo not shown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected TCF7L2 to oligodendrocyte biology, showing remyelination-specific expression and a selective Olig2 (not Olig1) protein complex.\",\n      \"evidence\": \"Co-IP and cuprizone demyelination/remyelination mouse model with temporal expression\",\n      \"pmids\": [\"22160878\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the Olig2 complex not tested here\", \"Direct target genes in oligodendrocytes not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Dissected TCF7L2 splice-variant function in β-cells, showing isoform-specific opposite effects on survival, function, and Wnt activity, with depletion activating GSK3β.\",\n      \"evidence\": \"Variant overexpression/knockdown in human islets, apoptosis and GSIS assays, TOPflash, GSK3β activity\",\n      \"pmids\": [\"21357677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous isoform ratios in disease not quantified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated a cell-autonomous β-cell requirement for TCF7L2 in glucose-stimulated insulin secretion, incretin response, and mass expansion.\",\n      \"evidence\": \"Pdx1-Cre conditional KO, GTT, isolated islet GSIS, and beta cell mass tomography\",\n      \"pmids\": [\"22717537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct islet target genes not defined in this study\", \"Relation to T2D risk allele not addressed here\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined a hepatic anti-gluconeogenic mechanism: TCF7L2 binds gluconeogenic promoters and blocks CREB/CRTC2/FoxO1 occupancy, with knockdown raising glucose and a nuclear isoform rescuing hyperglycemia.\",\n      \"evidence\": \"ChIP, siRNA knockdown, adenoviral overexpression, and in vivo GTT\",\n      \"pmids\": [\"23028378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-regulator basis of CREB/FoxO1 displacement unresolved\", \"Isoform-specific contributions not fully separated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Placed hepatic TCF7L2 downstream of insulin signaling as a repressor of gluconeogenesis, with insulin inducing TCF7L2 and β-catenin Ser675 phosphorylation.\",\n      \"evidence\": \"Hepatocyte siRNA, in vivo lithium Wnt activation, TOPGAL reporter, and glucose production assays\",\n      \"pmids\": [\"22967502\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct insulin-to-TCF7L2 transcriptional link not fully mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Linked TCF7L2 overexpression to ductal-to-islet regeneration via JAK2/STAT3, expanding its role to β-cell neogenesis.\",\n      \"evidence\": \"Adenoviral overexpression in exocrine cells with JAK2/STAT3 inhibition and in vivo HFD/STZ models\",\n      \"pmids\": [\"22945304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contribution of this pathway uncertain\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined a pancreatic islet transcriptional network in which ISL1 is a primary direct TCF7L2 target controlling proinsulin production, and linked the rs7903146 risk allele to altered TCF7L2 expression and insulin content.\",\n      \"evidence\": \"RNA-seq of rodent and human islets with TCF7L2 manipulation and genotype-stratified human islet profiling\",\n      \"pmids\": [\"25015099\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direction of allelic effect on TCF7L2 activity debated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Mapped genome-wide direct hepatic TCF7L2 targets and revealed mutual antagonism with HNF4α in metabolic gene regulation.\",\n      \"evidence\": \"ChIP-seq, time-course RNA-seq after silencing, and co-siRNA epistasis for HNF4α\",\n      \"pmids\": [\"25414334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of HNF4α chromatin displacement not resolved\", \"In vivo confirmation of the HNF4α interplay limited\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked LRP6-dependent Wnt signaling to TCF7L2 activity in vascular smooth muscle, where diminished TCF7L2 promotes Sp1/PDGF-driven dedifferentiation rescuable by Wnt3a.\",\n      \"evidence\": \"LRP6(R611C) knock-in mice, carotid injury model, and Wnt3a rescue\",\n      \"pmids\": [\"26489464\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TCF7L2 VSMC targets not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed TCF7L2 is required for thalamic-specific lithium-induced nuclear translocation of β-catenin, establishing a tissue-selective gating of Wnt nuclear signaling.\",\n      \"evidence\": \"Lentiviral silencing, ectopic expression in cortical neurons, nuclear fractionation, and zebrafish behavioral knockdown\",\n      \"pmids\": [\"27793772\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of thalamic specificity unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established a cell-autonomous α-cell role for TCF7L2 in glucagon secretion, α-cell mass, and counter-regulatory hypoglycemic responses.\",\n      \"evidence\": \"Alpha cell-selective KO with hyperinsulinaemic-hypoglycaemic clamp and islet glucagon assays\",\n      \"pmids\": [\"28343277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct α-cell target genes not enumerated\", \"Mechanism of low-glucose secretion control unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed a paracrine mechanism: pericytic TCF7L2 supports β-cell function via secreted factors including BMP4, with exogenous BMP4 rescuing impaired insulin secretion.\",\n      \"evidence\": \"Pericyte-specific conditional KO, GTT, islet GSIS, and BMP4 rescue\",\n      \"pmids\": [\"29246974\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full secretome mediating the effect not defined\", \"Direct BMP4 promoter regulation in pericytes not shown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established that TCF7L2 HMG-box DNA-binding function in adipocytes regulates Wnt signaling during adipogenesis and is required for systemic glucose homeostasis.\",\n      \"evidence\": \"3T3-L1 adipogenesis assays, adipocyte-specific HMG-box deletion mice, ChIP-seq, and RNA-seq\",\n      \"pmids\": [\"29317436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Distinction between DNA-binding-dependent and -independent functions incomplete\", \"Specific causal adipocyte targets not pinpointed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed TCF7L2 directly represses PIK3R1 to activate PI3K/AKT and stimulate β-cell insulin secretion.\",\n      \"evidence\": \"ChIP-PCR, luciferase reporter, knockdown/overexpression, and insulin secretion ELISA\",\n      \"pmids\": [\"31312258\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo confirmation lacking\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified TCF7L2/EGR1 synergistic activation of LCN2 via ERK signaling in a positive feedback loop, extending TCF7L2 to ERK-coupled transcription.\",\n      \"evidence\": \"ChIP, deletion-mapped reporters, MEK inhibitor epistasis, and migration/invasion assays\",\n      \"pmids\": [\"30557604\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of the loop unestablished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined adipocyte-autonomous TCF7L2 control of lipid and glucose metabolic genes, with deletion causing hypertrophy, insulin resistance, and impaired lipolysis.\",\n      \"evidence\": \"Adipoq-Cre KO, HFD challenge, ChIP-seq, RNA-seq, and lipolysis assays\",\n      \"pmids\": [\"30948248\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy of direct vs secondary metabolic targets incomplete\", \"Crosstalk with hepatic phenotype not dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed MALAT1 enhances TCF7L2 mRNA translation via SRSF1 and the mTORC1-4EBP1 axis, adding a post-transcriptional layer to TCF7L2 regulation relevant to glucose metabolism and tumorigenicity.\",\n      \"evidence\": \"Polysome fractionation, 5′UTR reporters, mTOR inhibition, and siRNA epistasis\",\n      \"pmids\": [\"30914432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct MALAT1-TCF7L2 mRNA interaction not fully demonstrated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a brain-pancreas axis in which medial habenular TCF7L2 regulates nicotinic receptor function and nicotine-induced glucose dysregulation through a polysynaptic mHb-to-pancreas circuit.\",\n      \"evidence\": \"Viral mHb inhibition, nicotine self-administration, circuit tracing, and mutant Tcf7l2 rats\",\n      \"pmids\": [\"31619789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets mediating nAChR control not defined\", \"Molecular link from mHb signaling to islet output incomplete\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined TCF7L2 as a thalamic terminal selector controlling postmitotic differentiation, connectivity, and firing properties through direct target genes.\",\n      \"evidence\": \"Embryonic and postnatal conditional KO, electrophysiology, ChIP, and RNA-seq\",\n      \"pmids\": [\"32675279\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full direct target set incompletely catalogued\", \"Mechanism of terminal-selector specificity unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed adipocyte TCF7L2 loss produces sexually dimorphic glucose intolerance and altered incretin/NEFA profiles, implicating adipocyte-to-islet/enteroendocrine crosstalk.\",\n      \"evidence\": \"Adipoq-Cre KO with chow/HFD, GSIS, incretin and lipid measurements\",\n      \"pmids\": [\"33068125\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proposed paracrine/endocrine mediators not directly demonstrated\", \"Basis of sex dimorphism unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the oligodendrocyte differentiation mechanism: TCF7L2 directly represses Bmp4, and BMP4 deletion rescues differentiation arrested by TCF7L2 loss.\",\n      \"evidence\": \"Oligodendrocyte and BMP4 conditional KOs, compound genetic epistasis, ChIP, and in vitro differentiation\",\n      \"pmids\": [\"33452226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-factors at the Bmp4 element not identified\", \"Wnt-dependence of this repression not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Associated VSMC TCF7L2 upregulation with BCL2 repression and apoptosis as a candidate driver of thoracic aortic aneurysm, supported by aortic eQTL colocalization.\",\n      \"evidence\": \"In vitro VSMC overexpression with BCL2 readout and eQTL colocalization\",\n      \"pmids\": [\"34265237\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single in vitro molecular readout (BCL2); no in vivo causal test\", \"Direct BCL2 promoter regulation not shown\", \"Disease link rests on colocalization\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Causally linked impaired TCF7L2-dependent transcription to poor myelination in Huntington's disease by restoring remyelination with Tcf7l2 overexpression.\",\n      \"evidence\": \"RNA-seq/proteomics of HD white matter and in vivo Tcf7l2 overexpression rescue in R6/2 mice\",\n      \"pmids\": [\"36044851\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism repressing TCF7L2 in HD unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established TCF7L2 as the dominant astrocytic Wnt effector controlling astrocyte maturation, tiling, gap-junction coupling, and synapse-number restriction with behavioral consequences.\",\n      \"evidence\": \"Postnatal astrocyte-specific conditional KO with morphology, coupling, synapse, and behavioral assays\",\n      \"pmids\": [\"37798419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct astrocytic target genes restricting synapse number not defined\", \"Molecular link to behavioral phenotype incomplete\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TCF7L2 selects activation versus repression and tissue-specific direct target sets across its many roles, and which co-regulator/isoform configurations drive each context, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Unified model linking isoform/co-regulator composition to activator vs repressor output is lacking\", \"Tissue-specific direct target catalogs only partially defined\", \"Mechanism of tissue-selective β-catenin gating not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 9, 12, 16, 20, 21, 27, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9, 12, 16, 21, 27, 28]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 4, 22]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [2, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 13, 22, 26, 28]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 9, 12, 16, 20, 21]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [9, 12, 17, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 20, 21, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CTNNB1\", \"JUP\", \"HIC1\", \"OLIG2\", \"HNF4A\", \"EGR1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}